Sanford C. Bernstein Reiterates Buy Rating for Bayer AG (BAYRY)
Other analysts also recently issued research reports about the stock. Zacks Investment Research downgraded shares of Bayer AG from a buy rating to a hold rating in a report on Monday, July 11th. DZ Bank AG restated a buy rating on shares of Bayer AG in a report on Wednesday, May 25th. JPMorgan Chase & Co. restated a neutral rating on shares of Bayer AG in a report on Tuesday, May 24th. Commerzbank AG upgraded shares of Bayer AG from a hold rating to a buy rating in a report on Wednesday, May 25th. Finally, Deutsche Bank AG restated a buy rating on shares of Bayer AG in a report on Wednesday, May 25th. Six investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. The company presently has an average rating of Buy and a consensus price target of $124.50.
Bayer AG (OTCMKTS:BAYRY) opened at 102.90 on Thursday. The firm has a market cap of $85.09 billion, a price-to-earnings ratio of 16.84 and a beta of 1.40. The stock’s 50 day moving average is $107.05 and its 200-day moving average is $107.71. Bayer AG has a 12 month low of $94.36 and a 12 month high of $135.71.
About Bayer AG
Bayer AG is a Germany-based chemical and pharmaceutical company. The Company’s business operations are organized into three segments: Bayer HealthCare, Bayer CropScience and Bayer MaterialScience, supported by the service companies Bayer Business Services, Bayer Technology Services and Currenta. Bayer HealthCare researches, develops, manufactures and markets products to improve the health of people and animals.
Receive News & Ratings for Bayer AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer AG and related companies with Analyst Ratings Network's FREE daily email newsletter.